Capstone Wealth Management Group (Pennsylvania)’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-6,108
Closed -$313K 60
2022
Q4
$313K Buy
6,108
+96
+2% +$4.6K 0.34% 48
2022
Q3
$263K Buy
6,012
+51
+0.9% +$2.48K 0.34% 50
2022
Q2
$313K Buy
5,961
+45
+0.8% +$2.29K 0.38% 47
2022
Q1
$306K Buy
5,916
+64
+1% +$3.32K 0.31% 53
2021
Q4
$346K Buy
+5,852
New +$290K 0.28% 57

Other funds holding PFE

Capstone Wealth Management Group (Pennsylvania)'s PFE Position: Q1 2023 in Review

Capstone Wealth Management Group (Pennsylvania) sold out of Pfizer (PFE) in Q1 2023, closing a stake of 6,108 shares — an estimated $313K sold.

Capstone Wealth Management Group (Pennsylvania) first reported a position in PFE in Q4 2021 and held it in 5 quarters. The position peaked at $346K in Q4 2021. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Capstone Wealth Management Group (Pennsylvania) reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Capstone Wealth Management Group (Pennsylvania) sold 6,108 Pfizer shares in Q1 2023, an estimated $313K.
  • Capstone Wealth Management Group (Pennsylvania) first reported a position in Pfizer in Q4 2021 and held it in 5 quarters.
  • Capstone Wealth Management Group (Pennsylvania)'s Pfizer position peaked at $346K in Q4 2021.
  • 3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Capstone Wealth Management Group (Pennsylvania)'s 13F filing for Q1 2023, filed 13 Apr 2023.